A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
• 作者

  Ghobrial Irene M.; Liu Chia-Jen; Perez Raymond P.; Richardson Paul; Anderson Kenneth C.; Laubach Jacob; Henrick Patrick; Savell Alexandra; Reyes Kaitlen; Hornburg Kalvis; Chuma Stacey; Sabbatini Peter; Becker Pamela S.;

  展开▼
• 作者单位

  Harvard Med Sch Dana Farber Canc Inst Dept Med Oncol Boston MA USA;

  Harvard Med Sch Dana Farber Canc Inst Dept Med Oncol Boston MA USA;

  Univ Kansas Canc Ctr Kansas City KS USA;

  Harvard Med Sch Dana Farber Canc Inst Dept Med Oncol Boston MA USA;

  Harvard Med Sch Dana Farber Canc Inst Jerome Lipper Multiple Myeloma Ctr Dept Med Oncol LeBow;

  Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;

  Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;

  Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;

  Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;

  Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;

  Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;

  Bristol Myers Squibb Princeton NJ USA;

  Univ Washington Fred Hutchinson Canc Res Ctr Div Hematol Seattle WA 98195 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词